IN THE SPECIFICATION:

Please replace the paragraph on page 1, lines 4-5, with the following amended paragraph:

This application <u>is a divisional of commonly assigned, co-pending application 09/836,385, filed April 17, 2001, which claims benefit of U.S. provisional patent application no. 60/198,488, filed April 18, 2000, each of which is incorporated by reference.</u>

Please replace the paragraph on page 4, lines 2-18, with the following amended paragraph:

The invention is based, in part, on the surprising discovery that the cytokine designated IL-174 has roles in various aspects of immune responses. The IL-174 is one of a family of genes encoding proteins which exhibit structural features characteristic of cytokines, particularly related to the cytokine designated CTLA-8 (also referred to as IL-17). Rat, mouse, human forms and a viral homolog of CTLA-8 have been described and their sequences available from GenBank. See Rouvier, et al. (1993) <u>J. Immunol.</u> 150:5445-5456; Yao, et al. (1995) <u>Immunity</u> 3:811-821; Yao, et al. (1995) <u>J. Immunol.</u> 155:5483-5486; and Kennedy, et al. (1996) <u>J. Interferon and</u> Cytokine Res. 16:611-617. The CTLA-8 has activities implicated in arthritis, kidney graft rejection, tumorigenicity, virus-host interactions, and innate immunity; and appears to exhibit certain regulatory functions similar to IL-6. See PubMed (search for IL-17); Chabaud, et al. (1998) <u>J. Immunol.</u> 63:139-148 161:409-414; Amin, et al. (1998) <u>Curr.</u> Opin. Rheumatol. 10:263-268; Van Kooten, et al. (1998) J. Am. Soc. Nephrol. 9:1526-1534; Fossiez, et al. (1998) <u>Int. Rev. Immunol.</u> 16:541-551; Knappe, et al. (1998) <u>J.</u> Virol. 72:5797-5801; Seow (1998) Vet. Immuno. Immunopathol. 63:139-48; and Teunissen, et al. (1998) J. Invest. Dermatol. 111:645-649. A report on the signaling through the NFkB transcription factor implicates a signal pathway which is used in innate immunity. Shalom-Barak, et al. (1998) <u>J. Biol. Chem.</u> 273:27467-27473.

Docket: DX01088KB